Javascript must be enabled to continue!
The impact of idiopathic childhood‐onset growth hormone deficiency (GHD) on bone mass in subjects without adult GHD
View through CrossRef
Summaryobjective Despite seemingly adequate growth hormone (GH) treatment during childhood, children with GH deficiency (GHD) have reduced bone mineral density (BMD) at final height. The aim was to evaluate BMD and bone mineral content (BMC) in adults treated for idiopathic childhood‐onset (CO) GHD, 18 years after stopping GH treatment.subjects and methods Twenty‐six (11 females) patients with idiopathic CO GHD participated. All patients but two had been treated for isolated GHD in childhood. The childhood diagnosis was established by an insulin tolerance test (ITT) and reassessed in adulthood by an ITT (N = 21) or arginine test (n = 5), revealing that 10 patients had GHD according to adult criteria. Accordingly, the patient group was divided into (1) patients who did not have persistent GHD in adulthood and (2) patients who did have persistent adult GHD. Twenty‐six healthy subjects acted as age‐, gender‐ and body mass index (BMI)‐matched controls.results The patients who did not have persistent GHD had significantly lower IGF‐I values and whole‐body, femoral neck and lumbar spine BMD compared to controls [0·994 ± 0·10 vs. 1·114 ± 0·11 g/cm2 (P = 0·003), 0·842 ± 0·12 vs. 0·962 ± 0·11 g/cm2 (P = 0·006) and 1·026 ± 0·14 vs. 1·127 ± 0·13 g/cm2 (P = 0·004), respectively]. Femoral neck BMD was significantly reduced in the patients who had persistent GHD, compared to controls (0·842 ± 0·09 vs. 0·938 ± 0·11, P = 0·04). Significant correlations were observed between all bone variables and IGF‐I in all subjects, whereas no correlations were observed between bone variables and GH peak levels in the 26 patients.conclusion In conclusion, we found that (1) patients with idiopathic CO GHD, who at retest in adulthood did not have GHD according to adult criteria, had reduced serum IGF‐I and BMD/BMC compared to controls. (2) This observation was also made in the patients who did have persistent GHD in adulthood. The findings may reflect the fact that the present diagnostic criteria for adult GHD (i.e. response to the ITT) do not reflect the clinical consequences of disordered GH–IGF axis in CO GHD young adults who were treated with GH in childhood. Alternatively, despite seemingly adequate GH treatment in childhood an optimal peak bone mass in adolescence may never have been reached in either of the groups. (3) IGF‐I levels correlated with clinical signs of the adult GHD syndrome. We believe that further studies on the indications and diagnostic procedures for GH treatment after cessation of linear growth are necessary.
Title: The impact of idiopathic childhood‐onset growth hormone deficiency (GHD) on bone mass in subjects without adult GHD
Description:
Summaryobjective Despite seemingly adequate growth hormone (GH) treatment during childhood, children with GH deficiency (GHD) have reduced bone mineral density (BMD) at final height.
The aim was to evaluate BMD and bone mineral content (BMC) in adults treated for idiopathic childhood‐onset (CO) GHD, 18 years after stopping GH treatment.
subjects and methods Twenty‐six (11 females) patients with idiopathic CO GHD participated.
All patients but two had been treated for isolated GHD in childhood.
The childhood diagnosis was established by an insulin tolerance test (ITT) and reassessed in adulthood by an ITT (N = 21) or arginine test (n = 5), revealing that 10 patients had GHD according to adult criteria.
Accordingly, the patient group was divided into (1) patients who did not have persistent GHD in adulthood and (2) patients who did have persistent adult GHD.
Twenty‐six healthy subjects acted as age‐, gender‐ and body mass index (BMI)‐matched controls.
results The patients who did not have persistent GHD had significantly lower IGF‐I values and whole‐body, femoral neck and lumbar spine BMD compared to controls [0·994 ± 0·10 vs.
1·114 ± 0·11 g/cm2 (P = 0·003), 0·842 ± 0·12 vs.
0·962 ± 0·11 g/cm2 (P = 0·006) and 1·026 ± 0·14 vs.
1·127 ± 0·13 g/cm2 (P = 0·004), respectively].
Femoral neck BMD was significantly reduced in the patients who had persistent GHD, compared to controls (0·842 ± 0·09 vs.
0·938 ± 0·11, P = 0·04).
Significant correlations were observed between all bone variables and IGF‐I in all subjects, whereas no correlations were observed between bone variables and GH peak levels in the 26 patients.
conclusion In conclusion, we found that (1) patients with idiopathic CO GHD, who at retest in adulthood did not have GHD according to adult criteria, had reduced serum IGF‐I and BMD/BMC compared to controls.
(2) This observation was also made in the patients who did have persistent GHD in adulthood.
The findings may reflect the fact that the present diagnostic criteria for adult GHD (i.
e.
response to the ITT) do not reflect the clinical consequences of disordered GH–IGF axis in CO GHD young adults who were treated with GH in childhood.
Alternatively, despite seemingly adequate GH treatment in childhood an optimal peak bone mass in adolescence may never have been reached in either of the groups.
(3) IGF‐I levels correlated with clinical signs of the adult GHD syndrome.
We believe that further studies on the indications and diagnostic procedures for GH treatment after cessation of linear growth are necessary.
Related Results
The Growth Hormone Deficiency (GHD) Reversal Trial: Effect on final height of discontinuation versus continuation of growth hormone treatment in pubertal children with isolated GHD – A non-inferiority randomised controlled trial (RCT).
The Growth Hormone Deficiency (GHD) Reversal Trial: Effect on final height of discontinuation versus continuation of growth hormone treatment in pubertal children with isolated GHD – A non-inferiority randomised controlled trial (RCT).
Abstract
The GHD Reversal trial is a non-inferiority RCT (ISRCTN12552768) funded by the NIHR HTA Programme (NIHR127468)
Background: Growth hormone deficiency (GHD) is the c...
Determinants of IGF‐I status in a large cohort of growth hormone‐deficient (GHD) subjects: the role of timing of onset of GHD
Determinants of IGF‐I status in a large cohort of growth hormone‐deficient (GHD) subjects: the role of timing of onset of GHD
Summarybackground IGF‐I standard deviation score (SDS) is widely used in clinical practice; however, factors determining IGF‐I SDS in GH‐deficient (GHD) individuals remain incompl...
Do All Patients with Childhood-Onset Growth Hormone Deficiency (GHD) and Ectopic Neurohypophysis Have Persistent GHD in Adulthood?
Do All Patients with Childhood-Onset Growth Hormone Deficiency (GHD) and Ectopic Neurohypophysis Have Persistent GHD in Adulthood?
Cerebral magnetic resonance imaging findings are of great value for the diagnosis of nonacquired GH deficiency (GHD), and ectopic posterior pituitary hyperintense signal (EPPHS) is...
Retrospective analysis of early growth patterns in children diagnosed growth hormone deficient during childhood.
Retrospective analysis of early growth patterns in children diagnosed growth hormone deficient during childhood.
This retrospective study examines early growth patterns in children diagnosed with Growth Hormone Deficiency (GHD) during childhood. It highlights the significance of early detecti...
Systemic ghrelin levels in subjects with growth hormone deficiency are not modified by one year of growth hormone replacement therapy
Systemic ghrelin levels in subjects with growth hormone deficiency are not modified by one year of growth hormone replacement therapy
OBJECTIVE: Ghrelin stimulates growth hormone (GH) secretion both in vivo and in vitro. Ghrelin is mainly produced in and released from the stomach but it is probably also produced ...
Mortality and socioeconomic status in adults with childhood onset GH deficiency (GHD) is highly dependent on the primary cause of GHD
Mortality and socioeconomic status in adults with childhood onset GH deficiency (GHD) is highly dependent on the primary cause of GHD
Objective
Childhood onset GH deficiency (CO-GHD) is associated with increased morbidity and mortality; however, the patients' socioeconomic profile as adults is not fully known.
...
The Cardiovascular Risk of Adult GH Deficiency (GHD) Improved after GH Replacement and Worsened in Untreated GHD: A 12-Month Prospective Study
The Cardiovascular Risk of Adult GH Deficiency (GHD) Improved after GH Replacement and Worsened in Untreated GHD: A 12-Month Prospective Study
Increased cardiovascular morbidity and mortality were reported in GH deficiency (GHD), and GH replacement can ameliorate cardiac abnormalities of adult GHD patients. To test the po...
Growth Hormone (GH) Deficiency (GHD) of Childhood Onset: Reassessment of GH Status and Evaluation of the Predictive Criteria for Permanent GHD in Young Adults
Growth Hormone (GH) Deficiency (GHD) of Childhood Onset: Reassessment of GH Status and Evaluation of the Predictive Criteria for Permanent GHD in Young Adults
GH secretion was reevaluated after completion of GH treatment at a mean age of 19.2 ± 3.2 yr in 35 young adults with childhood-onset GH deficiency (GHD). The patients were subdivid...

